23 results
SC 14F1
OPGN
Opgen Inc
3 Apr 24
Statement regarding change in majority of directors
5:29pm
transactions for potential conflict of interest situations and approving all such transactions; and
reviewing quarterly earnings releases
424B3
OPGN
Opgen Inc
3 May 23
Prospectus supplement
4:43pm
and regulatory requirements;
reviewing all related person transactions for potential conflict of interest situations and approving all such transactions
8-K
EX-1.1
06w3j fqt4tyo4
24 Jun 22
Entry into a Material Definitive Agreement
4:37pm
8-K
EX-1.1
hqly6k65qt5r55
13 Nov 20
First commercial orders completed, assay design based on proprietary ARESdb to comprehensively cover antibiotic resistance markers
4:52pm
8-K
EX-1.1
blc4zx
12 Feb 20
Entry into a Material Definitive Agreement
9:25am
S-4/A
EX-10.39.1
zo1hg2u
20 Dec 19
Registration of securities issued in business combination transactions (amended)
5:28pm
8-K
EX-10.1
1y1 evxpav
24 Sep 18
Departure of Directors or Certain Officers
8:31pm